Fresenius Kabi to purchase transfusion specialist Fenwal Holdings

Fresenius Kabi has signed an agreement to purchase the transfusion technology specialist Fenwal Holdings from TPG and Maverick Capital.

The acquired firm is a prominent creator of products for blood collection, separation and processing, employing around 4,900 people worldwide, while operating five manufacturing facilities and a research and development centre.

Buying the company represents an important step in Fresenius Kabi's growth strategy, making it a global leader in the transfusion sector and helping to create a more balanced product portfolio.

Fresenius Kabi is already a major supplier of blood bags and filters for manual blood collection, meaning the addition of Fenwal will be highly complementary.

Ulf Mark Schneider, chief executive officer of Fresenius, said: "Acquiring Fenwal is a unique opportunity to significantly expand Fresenius Kabi's medical devices/transfusion technology segment."

Last month, Fresenius Kabi raised its expectations for 2012, based on the substantial growth it has experienced across all segments during the year so far.